1 / 15

SINGAPORE

SINGAPORE. The Biopolis of Asia By: Luanne Theseira Commercial Specialist U.S. Commercial Service, Singapore Email: Luanne.Theseira@mail.doc.gov. Singapore – The Biopolis of Asia. Global Biomedical Services Hub Advancing Human Healthcare. Regional HQ. Product & Process Development.

Donna
Télécharger la présentation

SINGAPORE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SINGAPORE The Biopolis of Asia By: Luanne Theseira Commercial Specialist U.S. Commercial Service, Singapore Email: Luanne.Theseira@mail.doc.gov

  2. Singapore – The Biopolis of Asia Global Biomedical Services Hub Advancing Human Healthcare Regional HQ Product & Process Development Full-scale Manufacturing Basic & Clinical Research Healthcare Delivery Marketing Source: EDB Singapore

  3. Strong IP Protection World Intellectual Property Office Madrid Protocol Berne Convention Singapore is signatory to major IPR conventions & treaties Budapest Treaty Paris Convention Trade Related Aspects of IPR (TRIPS) Patent Cooperation Treaty (PCT) Nice Agreement “Singapore has a solid infrastructure, strong government support for the biomedical sciences industry, sound intellectual property protection and excellent opportunities for synergistic local collaborations.” Managing Director, Lilly Systems Biology Source: EDB Singapore

  4. ProcessesBiomedical Sciences Cluster Medical Technology Biomarkers Pharmaceutical Services Drug Discovery Bioprocessing Genomics & Proteomics Molecular & Cell Biology Bioengineering & Nanotechnology Computational Biology Healthcare Services & Delivery Stem Cells Bioimaging Biotechnology Source: EDB Singapore

  5. VISION To develop Singapore as the Healthcare Services Hub in Asia. Already the regional hub for South East Asia. - Expand from less than 1% in 2000 to 3% by 2012. => Represent 1 million foreign patients contributing $2.6 billion of value-add or 1% more to GDP

  6. Singapore – Healthcare Services Hub in Asia • Recognizes the potential growth in regional demand • Asia’s population will expand from 3.2 billion to 5. 6 billion in 2050. • Consumer expenditure on healthcare services and healthcare goods is expected to grow to US$188 billion in 2013.

  7. Singapore – Healthcare System, Health Status and Best Prospects • Government Expenditure stands at 0.9% of GDP ðlower than any developed country ðpopulation is much younger at present ð  as population ages, health expenditure will be higher Singapore Government is looking at ways to address the problem of rising healthcare costs

  8. Healthcare Financing Singapore has a hybrid healthcare financing framework Two Key Principles :- • Individual Responsibility • Community and Govt. support for those in need

  9. Primary Healthcare Services / Hospital Care Primary Healthcare • 80% of the primary healthcare services is provided by the private practitioners • 20% by the Govt polyclinics Hospital Care • 80% of hospital care provided by public sector • 20% by the private sector

  10. Health Facts • Cancer – Biggest Killer in Singapore • Heart Disease –2nd Most Common Cause of death • Stroke– 4th Most Common • Diabetes Mellitus – 8% of population diabetic, accounts for 8% of all deaths AIM => to identify these early and take preventive or corrective steps promptly.

  11. Health Sciences Authority (HSA) SINGAPORE’S EQUIVALENT OF THE FDA • Health Products Regulation Group • Health Products Bill tabled in Parliament in Jan 2007 • Adopts a Risk-Based Approach => Devices approved for use in the U.S., Europe, Japan and Australia are acceptable

  12. Future Challenges • The increasing cost of providing healthcare as a result of advances in medical knowledge and technology • Rising expectations and demand for better and more sophisticated health services by a more affluent public • Rapidly ageing population

  13. Future Plans • Health spending to reach US$2 billion a year within the next 5 years. => Currently, it is US$1.3 billion per year • 2 Plots of Land will go on sale in 2007 for the development of private hospitals • Expected to yield an additional 400 beds • In the Public Sector, approx. 910 beds will come on stream in 2007

  14. Best Prospects / Opportunities • Cutting-edge medical technology and equipment • Health Screening products • Point-of-Care Diagnostics • Preventive Care • Home Care • Infection Control Products

  15. Useful Websites

More Related